Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SCTX
Strong SellScribe Therapeutics Inc. · Healthcare · United States · $603M
1
StockRankGet insider-trade alerts
Q
10
V
25
M
22
P/E (TTM)
—
ROE
—
D/E
—
Dividend %
—
Loading 1Y...
PRICE (1Y)+49.9%
Close
$28.44
RSI (14)
55.6
SCORE BREAKDOWN
Quality
10
ROIC
-231.6%2.1
ROE
—N/A
GP/Assets
-25.3%4.1
Op. Margin
-556.5%10.2
FCF/Assets
-59.4%5.4
Piotroski
00.4
Int. Cover
-8.9x24.6
D/E Ratio
—N/A
Current Ratio
0.66x3.7
Value
25
P/E (TTM)
—N/A
EV/EBITDA
-6.5x25.0
P/FCF
—N/A
P/B
-0.5x25.0
P/S
14.1x22.2
Div Yield
—N/A
Momentum
22
52W High %
—N/A
RS 6M
—N/A
SMA 50/200
—N/A
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
-70%7.8
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$603M
P/E (Forward)
-9.2x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SCTX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SCTX | Scribe Therapeutics Inc.(you) | $603M | 1 | Strong Sell |
| PRME | Prime Medicine, Inc. | $589M | 1 | Strong Sell |
| PROK | ProKidney Corp. | $643M | 4 | Strong Sell |
| OCGN | Ocugen, Inc. | $461M | 1 | Strong Sell |
| EYPT | EyePoint, Inc. | $408M | 2 | Strong Sell |
| EIKN | Eikon Therapeutics, Inc. | $604M | 10 | Strong Sell |
| SPRY | ARS Pharmaceuticals, Inc. | $532M | 8 | Strong Sell |
| VOGX | Vogenx, Inc. | $427M | 4 | Strong Sell |
| CAPR | Capricor Therapeutics, Inc. | $395M | 3 | Strong Sell |
| ALLO | Allogene Therapeutics, Inc. | $701M | 9 | Strong Sell |
Peer medians: ROE -25.6% · P/E 29.5x · Gross margin 58.7%